Cytotoxicity of doxorubicin conjugated with C60 fullerene. Structural and in vitro studies
Kamila Butowska , Witold Kozak , Magdalena Zdrowowicz , Samanta Makurat , Michał Rychłowski , Aleksandra Hać , Anna Herman-Antosiewicz , Jacek Piosik , Janusz Rak
AbstractConjugating an anticancer drug of high biological efficacy but large cytotoxicity with a “transporting” molecule of low toxicity constitutes a valuable approach to design safe drug delivery system. In the present study, doxorubicin (DOX) a drug of large cardiotoxicity was chemically conjugated to a C60-fullerene. The synthesized molecule, a fullerene-doxorubicin conjugate (Ful-DOX), was characterized using the 1H NMR and MALDI TOF mass spectrometry. The absorption and fluorescence spectra and dynamic light scattering of the conjugate were recorded in an aqueous solution, while the impact on viability of several cancer cell lines of the free DOX and the conjugate was compared using the SRB and WST-1 assays. A low antiproliferative activity of the conjugate as compared to the free DOX is a consequence of the presence of fullerene moiety in the former, which is also responsible for the conjugate aggregation in an aqueous solution. Unlike free DOX, these aggregates cannot pass through the nuclear membrane (as demonstrated by the confocal microscopy measurements), which makes them marginally cytotoxic.
|Journal series||Structural Chemistry, ISSN 1040-0400, e-ISSN 1572-9001, (N/A 70 pkt)|
|Publication size in sheets||0.55|
|Keywords in English||Fullerene, doxorubicin, covalent conjugate, drug delivery, nanoparticle, cancer cells|
|License||Other; published final; ; with publication|
|Score||= 70.0, 28-01-2020, ArticleFromJournal|
|Publication indicators||= 0; : 2017 = 0.525; : 2018 = 1.624 (2) - 2018=1.333 (5)|
* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.